The newly launched MelaQuest Collection from DermaQuest is positioned as an effective at-home skincare solution for aesthetic clinics to promote to their patients. Developed through extensive medical research, the collection caters to all skin types and addresses key skin discoloration concerns, including hyperpigmentation, melasma, post-inflammatory marks, and sun damage.
A standout ingredient in the range is cysteamine, a naturally occurring amino acid that disrupts melanin production by inhibiting tyrosinase activity. Clinical studies have shown that cysteamine is 1.5 times more effective than hydroquinone at reducing pigmentation safely, with patients experiencing significant improvements in skin discoloration after just two months of use.
The MelaQuest Collection incorporates additional advanced ingredients to target pigmentation through multiple pathways. These include tranexamic acid, a proven tyrosinase inhibitor for dark spots and melasma; THD ascorbate, a lipid-soluble vitamin C derivative for environmental protection; and skin-brightening peptides, which influence melanin production. The collection also features kojic acid, which reduces pigmentation by inhibiting tyrosinase, and niacinamide, which blocks melanosome transfer and provides anti-inflammatory benefits.
Designed to complement in-clinic treatments, the collection aims to inhibit melanogenesis, reduce melanin transfer, accelerate cellular turnover, and prevent pigmentation recurrence. Its multi-targeted approach offers clinics a scientifically validated option to support patient outcomes effectively.
Comments